메뉴 건너뛰기




Volumn 34, Issue 31, 2013, Pages 2481-2489

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: Results of the RADAR trial

(18)  Povsic, Thomas J a   Vavalle, John P a   Aberle, Laura H a   Kasprzak, Jaroslaw D b   Cohen, Mauricio G c   Mehran, Roxana d   Bode, Christoph e   Buller, Christopher E f   Montalescot, Gilles g   Cornel, Jan H h   Rynkiewicz, Andrzej i   Ring, Michael E j   Zeymer, Uwe k   Natarajan, Madhu l   Delarche, Nicolas m   Zelenkofske, Steven L n   Becker, Richard C a   Alexander, John H a  


Author keywords

Acute coronary syndromes; Anticoagulation reversal; REG1

Indexed keywords

ACETYLSALICYLIC ACID; ANIVAMERSEN; CLOPIDOGREL; CREATINE KINASE MB; HEPARIN; PEGNIVACOGIN; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TROPONIN I; TROPONIN T;

EID: 84866743368     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs232     Document Type: Article
Times cited : (84)

References (30)
  • 1
    • 20444436800 scopus 로고    scopus 로고
    • Nucleic acid aptamers in therapeutic anticoagulation. Technology, development, and clinical application
    • Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development, and clinical application. Thromb Haemost 2005;93:1014-1020.
    • (2005) Thromb Haemost , vol.93 , pp. 1014-1020
    • Becker, R.C.1    Rusconi, C.2    Sullenger, B.3
  • 2
    • 77749298357 scopus 로고    scopus 로고
    • Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics
    • Becker RC, Povsic TJ, Cohen MG, Rusconi CP, Sullenger BA. Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost 2010;103:586-595.
    • (2010) Thromb Haemost , vol.103 , pp. 586-595
    • Becker, R.C.1    Povsic, T.J.2    Cohen, M.G.3    Rusconi, C.P.4    Sullenger, B.A.5
  • 4
    • 80052480929 scopus 로고    scopus 로고
    • Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: Translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design
    • Povsic TJ, Cohen MG, Chan MY, Zelenkofske SL, Wargin WA, Harrington RA, Alexander JH, Rusconi CP, Becker RC. Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. J Thromb Thrombolysis 2011;32:21-31.
    • (2011) J Thromb Thrombolysis , vol.32 , pp. 21-31
    • Povsic, T.J.1    Cohen, M.G.2    Chan, M.Y.3    Zelenkofske, S.L.4    Wargin, W.A.5    Harrington, R.A.6    Alexander, J.H.7    Rusconi, C.P.8    Becker, R.C.9
  • 5
    • 33845388596 scopus 로고    scopus 로고
    • First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
    • Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114:2490-2497.
    • (2006) Circulation , vol.114 , pp. 2490-2497
    • Dyke, C.K.1    Steinhubl, S.R.2    Kleiman, N.S.3    Cannon, R.O.4    Aberle, L.G.5    Lin, M.6    Myles, S.K.7    Melloni, C.8    Harrington, R.A.9    Alexander, J.H.10    Becker, R.C.11    Rusconi, C.P.12
  • 9
    • 79851499067 scopus 로고    scopus 로고
    • A randomized, partially-blinded, multicenter, activecontrolled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR phase IIb trial
    • Povsic TJ, Cohen MG, Mehran R, Buller CE, Bode C, Cornel JH, Kasprzak JD, Montalescot G, Joseph D, Wargin WA, Rusconi CP, Zelenkofske SL, Becker RC, Alexander JH. A randomized, partially-blinded, multicenter, activecontrolled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR phase IIb trial. Am Heart J 2011; 161:261-268.
    • (2011) Am Heart J , vol.161 , pp. 261-268
    • Povsic, T.J.1    Cohen, M.G.2    Mehran, R.3    Buller, C.E.4    Bode, C.5    Cornel, J.H.6    Kasprzak, J.D.7    Montalescot, G.8    Joseph, D.9    Wargin, W.A.10    Rusconi, C.P.11    Zelenkofske, S.L.12    Becker, R.C.13    Alexander, J.H.14
  • 11
    • 33845497457 scopus 로고    scopus 로고
    • Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite synergistic effects of factors XI and XII
    • Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite synergistic effects of factors XI and XII. Blood 2006;108:4045-4051.
    • (2006) Blood , vol.108 , pp. 4045-4051
    • Doggen, C.J.1    Rosendaal, F.R.2    Meijers, J.C.3
  • 12
    • 38349093597 scopus 로고    scopus 로고
    • Relationship between markers of activated coagulation, their correlation with inflammation, and association with heart disease (NPHSII)
    • Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Esnouf MP. Relationship between markers of activated coagulation, their correlation with inflammation, and association with heart disease (NPHSII). J Thromb Haemost 2008;6:259-267.
    • (2008) J Thromb Haemost , vol.6 , pp. 259-267
    • Miller, G.J.1    Ireland, H.A.2    Cooper, J.A.3    Bauer, K.A.4    Morrissey, J.H.5    Humphries, S.E.6    Esnouf, M.P.7
  • 13
    • 69949096467 scopus 로고    scopus 로고
    • Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): A randomised, double-blind, active-controlled, phase 2 trial
    • Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009; 374:787-795.
    • (2009) Lancet , vol.374 , pp. 787-795
    • Sabatine, M.S.1    Antman, E.M.2    Widimsky, P.3    Ebrahim, I.O.4    Kiss, R.G.5    Saaiman, A.6    Polasek, R.7    Contant, C.F.8    McCabe, C.H.9    Braunwald, E.10
  • 15
    • 0029744067 scopus 로고    scopus 로고
    • Transmission of a procoagulant signal from tissue factor-bearing cells to platelets
    • Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagul Fibrinolysis 1996;7: 459-464.
    • (1996) Blood Coagul Fibrinolysis , vol.7 , pp. 459-464
    • Monroe, D.M.1    Hoffman, M.2    Roberts, H.R.3
  • 16
    • 33645498094 scopus 로고    scopus 로고
    • Comparison of fondaparinux and enoxaparin in acute coronary syndromes
    • The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators
    • The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
    • (2006) N Engl J Med , vol.354 , pp. 1464-1476
  • 18
    • 65549102277 scopus 로고    scopus 로고
    • Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial
    • Gallo R, Steinhubl SR, White HD, Montalescot G. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial. Catheter Cardiovasc Intervent 2009;73:319-325.
    • (2009) Catheter Cardiovasc Intervent , vol.73 , pp. 319-325
    • Gallo, R.1    Steinhubl, S.R.2    White, H.D.3    Montalescot, G.4
  • 20
    • 0345872125 scopus 로고    scopus 로고
    • Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: Systematic review and meta-analysis
    • Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004; 291:350-357.
    • (2004) JAMA , vol.291 , pp. 350-357
    • Koreny, M.1    Riedmuller, E.2    Nikfardjam, M.3    Siostrzonek, P.4    Mullner, M.5
  • 21
    • 2442443079 scopus 로고    scopus 로고
    • A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention
    • Vaitkus PT. A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention. J Invasive Cardiol 2004;16:243-246.
    • (2004) J Invasive Cardiol , vol.16 , pp. 243-246
    • Vaitkus, P.T.1
  • 22
    • 77950126171 scopus 로고    scopus 로고
    • Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty
    • Biancari F, D'Andrea V, Marco CD, Savino G, Tiozzo V, Catania A. Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty. Am Heart J 2010;159:518-531.
    • (2010) Am Heart J , vol.159 , pp. 518-531
    • Biancari, F.1    D'Andrea, V.2    Marco, C.D.3    Savino, G.4    Tiozzo, V.5    Catania, A.6
  • 23
    • 79953017647 scopus 로고    scopus 로고
    • Radial artery access as a predictor of increased radiation exposure during a diagnostic cardiac catheterization procedure
    • Mercuri M, Mehta S, Xie C, Valettas N, Velianou JL, Natarajan MK. Radial artery access as a predictor of increased radiation exposure during a diagnostic cardiac catheterization procedure. JACC Cardiovasc Interv 2011;4:347-352.
    • (2011) JACC Cardiovasc Interv , vol.4 , pp. 347-352
    • Mercuri, M.1    Mehta, S.2    Xie, C.3    Valettas, N.4    Velianou, J.L.5    Natarajan, M.K.6
  • 25
    • 33746995205 scopus 로고    scopus 로고
    • Control of hyperuricemia in subjects with refractory gout, and induction of antibody against Poly(ethylene glucol) (PEG), in a phase i trial of subcutaneous PEGylated urate oxidase
    • Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against Poly(ethylene glucol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2005;8:R12.
    • (2005) Arthritis Res Ther , vol.8
    • Ganson, N.J.1    Kelly, S.J.2    Scarlett, E.3    Sundy, J.S.4    Hershfield, M.S.5
  • 26
    • 33947119693 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
    • Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007; 56:1021-1028.
    • (2007) Arthritis Rheum , vol.56 , pp. 1021-1028
    • Sundy, J.S.1    Ganson, N.J.2    Kelly, S.J.3    Scarlett, E.L.4    Rehrig, C.D.5    Huang, W.6    Hershfield, M.S.7
  • 27
    • 34250727437 scopus 로고    scopus 로고
    • Uricase and other novel agents for the management of patients with treament-failure gout
    • Sundy JS, Hershfield Michael S. Uricase and other novel agents for the management of patients with treament-failure gout. Curr Rheumatol Rep 2007;9:258-264.
    • (2007) Curr Rheumatol Rep , vol.9 , pp. 258-264
    • Sundy, J.S.1    Hershfield Michael, S.2
  • 28
    • 80054733922 scopus 로고    scopus 로고
    • RUBY-1: A randomized, doubleblind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM15)) following acute coronary syndrome
    • Steg PG, Mehta SR, Jukem JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB. RUBY-1: a randomized, doubleblind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM15)) following acute coronary syndrome. Eur Heart J 2011;32:2541-2554.
    • (2011) Eur Heart J , vol.32 , pp. 2541-2554
    • Steg, P.G.1    Mehta, S.R.2    Jukem, J.W.3    Lip, G.Y.4    Gibson, C.M.5    Kovar, F.6    Kala, P.7    Garcia-Hernandez, A.8    Renfurm, R.W.9    Granger, C.B.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.